Effect of thalidomide on stem cell collection and engraftment in patients with multiple myeloma

Bone Marrow Transplantation

Volumn 32, Issue 6, 2003, Pages 587-592

  Ghobrial, I M ^a   Dispenzieri, Angela ^a   Bundy, K L ^a   Gastineau, D A ^a   Rajkumar, S V ^a   Therneau, T M ^a   Lacy, M Q ^a   Witzig, T E ^a   Litzow, M R ^a   Christensen, B R ^a   Hayman, S ^a   Pribula, C G ^a   Gertz, M A ^a  

^a MAYO CLINIC   (United States)

Author keywords

Hematopoietic stem cells; Multiple myeloma; Platelet engraftment; Stem cell transplantation; Thalidomide

Indexed keywords

CARMUSTINE; CYCLOPHOSPHAMIDE; DEXAMETHASONE; DOXORUBICIN; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; LEXIDRONAM SAMARIUM SM 153; MELPHALAN; PREDNISONE; THALIDOMIDE; VINCRISTINE;

ADULT; AGED; ANTINEOPLASTIC ACTIVITY; ARTICLE; BONE MARROW BIOPSY; CLINICAL ARTICLE; CONTROLLED STUDY; FEMALE; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMAN; IMMUNOMODULATION; MALE; MAXIMUM TOLERATED DOSE; MULTIPLE MYELOMA; PRIORITY JOURNAL; RETROSPECTIVE STUDY; SINGLE DRUG DOSE; STATISTICAL SIGNIFICANCE; STEM CELL MOBILIZATION; THROMBOCYTE COUNT; THROMBOCYTE TRANSFUSION; WHOLE BODY RADIATION;

ADULT; AGED; BLOOD CELL COUNT; CASE-CONTROL STUDIES; GRAFT SURVIVAL; HEMATOPOIESIS; HEMATOPOIETIC STEM CELL MOBILIZATION; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; KINETICS; MIDDLE AGED; MULTIPLE MYELOMA; RETROSPECTIVE STUDIES; THALIDOMIDE; TRANSPLANTATION, AUTOLOGOUS;

EID: 10744230613     PISSN: 02683369     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.bmt.1704173     Document Type: Article

References (28)

1. Attal M, Harousseau JL, Stoppa AM et al. A prospective, randomized trial of autologous bone marrow transplantation and chemotherapy in multiple myeloma. Intergroupe Français du Myelome. N Engl J Med 1996; 335: 91-97.
2. Rajkumar SV, Kyle RA. Angiogenesis in multiple myeloma. Semin Oncol 2001; 28: 560-564.
3. Stirling D. Thalidomide: a novel template for anticancer drugs. Semin Oncol 2001; 28: 602-606.
4. Rajkumar SV. Thalidomide in multiple myeloma. Oncology (Huntingt) 2000; 14 (Suppl. 13): 11-16.
5. Singhal S, Mehta J, Desikan R et al. Antitumor activity of thalidomide in refractory multiple myeloma. N Engl J Med 1999; 341: 1565-1571.
6. Rajkumar SV, Dispenzieri A, Fonseca R et al. Thalidomide for previously untreated indolent or smoldering multiple myeloma. Leukemia 2001; 15: 1274-1276.
7. Weber DM, Rankin K, Gavino M et al. Thalidomide with dexamethasone for resistant multiple myeloma. Blood 2000; 96: 167a. (Abstr.).
8. Desikan RK, Jagannath S. Therapeutic dilemmas with thalidomide in multiple myeloma: case discussions. Semin Oncol 2001; 28: 593-596.
9. Goldschmidt H, Hegenbart U, Wallmeier M et al. Factors influencing collection of peripheral blood progenitor cells following high-dose cyclophosphamide and granulocyte colony-stimulating factor in patients with multiple myeloma. Br J Haematol 1997; 98: 736-744.
10. Kroger N, Zeller W, Hassan HT et al. Successful mobilization of peripheral blood stem cells in heavily pretreated myeloma patients with G-CSF alone. Ann Hematol 1998; 76: 257-262.
11. Prince HM, Imrie K, Sutherland DR et al. Peripheral blood pregenitor cell collections in multiple myeloma: Predictors and management of inadequate collections. Br J Haematol 1996; 93: 142-145.
12. Desikan KR, Jagannath S, Siegel D et al. Collection of more hematopoietic progenitor cells with large volume leukapheresis in patients with multiple myeloma. Leuk Lymphoma 1998; 28: 501-508.
13. Bensinger WI, Longin K, Appelbaum F et al. Peripheral blood stem cells (PBSCs) collected after recombinant granulocyte colony stimulating factor (rhG-CSF): an analysis of factors correlating with the tempo of engraftment after transplantation. Br J Haematol 1994; 87: 825-831.
14. Cappio FC, Cavo M, DeVincentiis A et al. Peripheral blood stem cell transplantation for the treatment of multiple myeloma: Biological and clinical implications. Haematologica 1996; 81: 356-375.
15. Tricot G, Jagannath S, Vesole D et al. Peripheral blood stem cell transplants for multiple myeloma: identification of favorable variables for rapid engraftment in 225 patients. Blood 1995; 85: 588-596.
16. Gertz MA, Lacy MQ, Inwards DJ et al. Factors influencing platelet recovery after blood cell transplantation in multiple myeloma. Bone Marrow Transplant 1997; 20: 375-380.
17. Kaplan EL, Meier P. Nonparametric estimation from incomplete observations. J Am Stat Assoc 1958; 53: 457-481.
18. Kyle RA, Rajkumar SV. Therapeutic application of thalidomide in multiple myeloma. Semin Oncol 2001; 28: 583-587.
19. Tosi P, Ronconi S, Zamagni E et al. Salvage therapy with thalidomide in multiple myeloma patients relapsing after autologous peripheral blood stem cell transplantation. Haematologica 2001; 86: 409-413.
20. Rajkumar SV, Fonseca R, Dispenzieri A et al. Thalidomide in the treatment of relapsed multiple myeloma. Mayo Clin Proc 2000; 75: 897-901.
21. Hideshima T, Chauhan D, Podar K et al. Novel therapies targeting the myeloma cell and its bone marrow microenvironment. Semin Oncol 2001; 28: 607-612.
22. D'Amato RJ, Lentzsch S, Anderson KC et al. Mechanism of action of thalidomide and 3-aminothalidomide in multiple myeloma. Semin Oncol 2001; 28: 597-601.
23. Rajkumar SV, Witzig TE. A review of angiogenesis and antiangiogenic therapy with thalidomide in multiple myeloma. Cancer Treat Rev 2000; 26: 351-362.
24. Kroger N, Zeller W, Hassan HT et al. Difference between expression of adhesion molecules on CD34+ cells from bone marrow and G-CSF-stimulated peripheral blood. Stem Cells 1998; 16: 49-53.
25. Nogueira AC, Neubert R, Helge H et al. Thalidomide and the immune system. 3. Simultaneous up- and down-regulation of different integrin receptors on human white blood cells. Life Sci 1994; 55: 77-92.
26. Geitz H, Handt S, Zwingenberger K. Thalidomide selectively modulates the density of cell surface molecules involved in the adhesion cascade. Immunopharmacology 1996; 31: 213-221.
27. Lichterfeld M, Martin S, Burkly L et al. Mobilization of CD34+ haematopoietic stem cells is associated with a functional inactivation of the integrin very late antigen 4. Br J Haematol 2000; 110: 71-81.
28. Byrne JL, Russell NH. Peripheral blood stem cell transplants. J Clin Pathol 1998; 51: 351-355.